BR100 Increased By (1.24%)
BR30 Increased By (1.33%)
KSE100 Increased By (1.2%)
KSE30 Increased By (1.26%)
AGHA 7.87 Increased By ▲ 0.12 (1.55%)
BECO 5.23 Increased By ▲ 0.04 (0.77%)
BML 59.80 Increased By ▲ 1.14 (1.94%)
BOP 34.36 Increased By ▲ 0.67 (1.99%)
CNERGY 10.93 Increased By ▲ 0.32 (3.02%)
CSIL 5.30 No Change ▼ 0.00 (0%)
FCCL 54.45 Increased By ▲ 0.71 (1.32%)
FFL 16.84 Increased By ▲ 0.38 (2.31%)
FNEL 1.23 Increased By ▲ 0.01 (0.82%)
KEL 7.47 Increased By ▲ 0.19 (2.61%)
KOSM 5.70 Increased By ▲ 0.06 (1.06%)
LOTCHEM 30.03 Increased By ▲ 0.38 (1.28%)
MLCF 97.17 Increased By ▲ 0.81 (0.84%)
NBP 206.10 Increased By ▲ 2.57 (1.26%)
NCPL 57.88 Increased By ▲ 1.03 (1.81%)
NPL 68.70 Increased By ▲ 1.39 (2.07%)
OGDC 321.15 Increased By ▲ 2.93 (0.92%)
PACE 10.75 Increased By ▲ 0.12 (1.13%)
PAEL 42.45 Increased By ▲ 0.68 (1.63%)
PIBTL 17.03 Increased By ▲ 0.22 (1.31%)
PPL 223.70 Increased By ▲ 3.53 (1.6%)
PRL 53.00 Increased By ▲ 3.95 (8.05%)
PTC 71.00 Increased By ▲ 0.99 (1.41%)
SSGC 29.56 Increased By ▲ 0.42 (1.44%)
TBL 9.92 Increased By ▲ 0.15 (1.54%)
TELE 8.91 Increased By ▲ 0.09 (1.02%)
TPL 17.33 Increased By ▲ 0.16 (0.93%)
TPLP 12.78 Increased By ▲ 0.27 (2.16%)
TREET 22.89 Increased By ▲ 0.30 (1.33%)
TRG 60.00 Decreased By ▼ -0.22 (-0.37%)
By

ROME: A top official in the European Medicines Agency said it might be worth abandoning AstraZeneca’s coronavirus vaccine for all age groups where alternatives are available, in an interview published Sunday.

Marco Cavaleri, the EMA’s head of vaccine strategy, also told Italy’s La Stampa newspaper that the Johnson & Johnson jab should be preferentially used for the over 60s.

Both so-called viral vector vaccines are authorised for everyone over 18 but have been dogged by reports of rare blood clots. The EU has also authorised two mRNA vaccines, Pfizer/BioNTech and Moderna.

Italy on Saturday restricted AstraZeneca vaccines to people aged 60 and over following concerns about the heightened health risks for younger people.

Asked if it would not be better to ban AstraZeneca including for the over 60s, Cavaleri said: “Yes, and it is an option that many countries, such as France and Germany, are considering in the light of the increased availability of mRNA vaccines.

“However, incidents were very rare and after the first dose. It is true that there is less data on the second dose, but in the United Kingdom it (the vaccination programme) is going well.”

He added: “Among young people the risks of illness decrease, and the message for them could be to use preferentially the mRNA vaccines, but the choice is left to individual states.”

Comments

Comments are closed for this article.